Online inquiry

IVTScrip™ mRNA-Human ADGRD1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK11334MR)

This product GTTS-WK11334MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the ADGRD1 protein. This product can be used in FGFR1 High NME5-epithelial cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001330497.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 283383
UniProt ID Q6QNK2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADGRD1, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WK11334MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK20299MR IVTScrip™ mRNA-Human ANKRD12, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ANKRD12
GTTS-WK15821MR IVTScrip™ mRNA-Human ANKRD36BP1, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANKRD36BP1
GTTS-WK9676MR IVTScrip™ mRNA-Human ABI3BP, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABI3BP
GTTS-WK8604MR IVTScrip™ mRNA-Human ADAMTS5, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADAMTS5
GTTS-WK26892MR IVTScrip™ mRNA-Human ASAP2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ASAP2
GTTS-WK14925MR IVTScrip™ mRNA-Human ANKRD42, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ANKRD42
GTTS-WK9471MR IVTScrip™ mRNA-Human ACTR2, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACTR2
GTTS-WK28703MR IVTScrip™ mRNA-Human ASCC2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASCC2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW